Health care providers' perceptions of using misoprostol in the treatment of incomplete abortion in Malawi.
Health care providers
Incomplete abortion
Malawi
Misoprostol
Perceptions
Post-abortion care
Unsafe Abortion
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
03 Dec 2022
03 Dec 2022
Historique:
received:
09
04
2022
accepted:
23
11
2022
entrez:
2
12
2022
pubmed:
3
12
2022
medline:
7
12
2022
Statut:
epublish
Résumé
In Malawi, abortion is only legal to save a pregnant woman's life. Treatment for complications after unsafe abortions has a massive impact on the already impoverished health care system. Even though manual vacuum aspiration (MVA) and misoprostol are the recommended treatment options for incomplete abortion in the first trimester, surgical management using sharp curettage is still one of the primary treatment methods in Malawi. Misoprostol and MVA are safer and cheaper, whilst sharp curettage has more risk of complications such as perforation and bleeding and requires general anesthesia and a clinician. Currently, efforts are being made to increase the use of misoprostol in the treatment of incomplete abortions in Malawi. To achieve successful implementation of misoprostol, health care providers' perceptions on this matter are crucial. A qualitative approach was used to explore health care providers' perceptions of misoprostol for the treatment of incomplete abortion using semi-structured in-depth interviews. Ten health care providers were interviewed at one urban public hospital. Each interview lasted 45 min on average. Health care providers of different cadres were interviewed in March and April 2021, nine months after taking part in a training intervention on the use of misoprostol. Interviews were recorded, transcribed verbatim and analyzed using 'Systematic Text Condensation'. The health care providers reported many advantages with the increased use of misoprostol, such as reduced workload, less hospitalization, fewer infections, and task-shifting. Availability of the drug and benefits for the patients were also highlighted as important. However, some challenges were revealed, such as deciding who was eligible for the drug and treatment failure. For these reasons, some health care providers still choose surgical treatment as their primary method. Findings in this study support the recommendation of increased use of misoprostol as a treatment for incomplete abortion in Malawi, as the health care providers interviewed see many advantages with the drug. To scale up its use, proper training and supervision are essential. A sustainable and predictable supply is needed to change clinical practice. Unsafe abortion is a major contributor to maternal mortality worldwide. Unsafe abortion is the termination of an unintended pregnancy by a person without the required skills or equipment, which might lead to serious complications. In Malawi, post-abortion complications are common, and the maternal mortality ratio is among the highest in the world. Retained products of conception, referred to as an incomplete abortion, are common after spontaneous miscarriages and unsafe induced abortions. There are several ways to treat incomplete abortion, and the drug misoprostol has been successful in the treatment of incomplete abortion in other low-income countries. This study explored perceptions among health care providers using misoprostol to treat incomplete abortions and whether the drug can be fully embraced by Malawian health care professionals. Health personnel at a Malawian hospital were interviewed individually regarding the use of the drug for treating incomplete abortions. This study revealed that health care providers interviewed are satisfied with the increased use of misoprostol. They highlighted several benefits, such as reduced workload and that it enabled task-shifting so that various hospital cadres could now treat patients with incomplete abortions. The health care workers also observed benefits for women treated with the drug compared to other treatments. The challenges mentioned were finding out who was eligible for the drug and drug failure. This study supports scaling up the use of misoprostol in the treatment of incomplete abortions in Malawi; the Ministry of Health and policymakers should support future interventions to increase its use.
Sections du résumé
BACKGROUND
BACKGROUND
In Malawi, abortion is only legal to save a pregnant woman's life. Treatment for complications after unsafe abortions has a massive impact on the already impoverished health care system. Even though manual vacuum aspiration (MVA) and misoprostol are the recommended treatment options for incomplete abortion in the first trimester, surgical management using sharp curettage is still one of the primary treatment methods in Malawi. Misoprostol and MVA are safer and cheaper, whilst sharp curettage has more risk of complications such as perforation and bleeding and requires general anesthesia and a clinician. Currently, efforts are being made to increase the use of misoprostol in the treatment of incomplete abortions in Malawi. To achieve successful implementation of misoprostol, health care providers' perceptions on this matter are crucial.
METHODS
METHODS
A qualitative approach was used to explore health care providers' perceptions of misoprostol for the treatment of incomplete abortion using semi-structured in-depth interviews. Ten health care providers were interviewed at one urban public hospital. Each interview lasted 45 min on average. Health care providers of different cadres were interviewed in March and April 2021, nine months after taking part in a training intervention on the use of misoprostol. Interviews were recorded, transcribed verbatim and analyzed using 'Systematic Text Condensation'.
RESULTS
RESULTS
The health care providers reported many advantages with the increased use of misoprostol, such as reduced workload, less hospitalization, fewer infections, and task-shifting. Availability of the drug and benefits for the patients were also highlighted as important. However, some challenges were revealed, such as deciding who was eligible for the drug and treatment failure. For these reasons, some health care providers still choose surgical treatment as their primary method.
CONCLUSION
CONCLUSIONS
Findings in this study support the recommendation of increased use of misoprostol as a treatment for incomplete abortion in Malawi, as the health care providers interviewed see many advantages with the drug. To scale up its use, proper training and supervision are essential. A sustainable and predictable supply is needed to change clinical practice. Unsafe abortion is a major contributor to maternal mortality worldwide. Unsafe abortion is the termination of an unintended pregnancy by a person without the required skills or equipment, which might lead to serious complications. In Malawi, post-abortion complications are common, and the maternal mortality ratio is among the highest in the world. Retained products of conception, referred to as an incomplete abortion, are common after spontaneous miscarriages and unsafe induced abortions. There are several ways to treat incomplete abortion, and the drug misoprostol has been successful in the treatment of incomplete abortion in other low-income countries. This study explored perceptions among health care providers using misoprostol to treat incomplete abortions and whether the drug can be fully embraced by Malawian health care professionals. Health personnel at a Malawian hospital were interviewed individually regarding the use of the drug for treating incomplete abortions. This study revealed that health care providers interviewed are satisfied with the increased use of misoprostol. They highlighted several benefits, such as reduced workload and that it enabled task-shifting so that various hospital cadres could now treat patients with incomplete abortions. The health care workers also observed benefits for women treated with the drug compared to other treatments. The challenges mentioned were finding out who was eligible for the drug and drug failure. This study supports scaling up the use of misoprostol in the treatment of incomplete abortions in Malawi; the Ministry of Health and policymakers should support future interventions to increase its use.
Identifiants
pubmed: 36461125
doi: 10.1186/s12913-022-08878-3
pii: 10.1186/s12913-022-08878-3
pmc: PMC9719115
doi:
Substances chimiques
Misoprostol
0E43V0BB57
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1471Subventions
Organisme : Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU)
ID : 2020/39645
Informations de copyright
© 2022. The Author(s).
Références
Rev Obstet Gynecol. 2009 Spring;2(2):122-6
pubmed: 19609407
Acta Obstet Gynecol Scand. 2011 Jul;90(7):692-700
pubmed: 21542813
BMJ Glob Health. 2018 Sep 23;3(5):e000823
pubmed: 30271625
PLoS One. 2014 Jun 25;9(6):e100728
pubmed: 24963882
BJOG. 2007 Nov;114(11):1337-9
pubmed: 17949375
Int J Surg. 2014;12(5):509-15
pubmed: 24560846
Int J Environ Res Public Health. 2018 Feb 21;15(2):
pubmed: 29466308
Malawi Med J. 2014 Dec;26(4):126-32
pubmed: 26167263
BMJ Glob Health. 2016 Jul 7;1(1):e000020
pubmed: 28588915
Br J Surg. 2017 Sep;104(10):1315-1326
pubmed: 28783227
Lancet. 2015 Jun 13;385(9985):2392-8
pubmed: 25817472
Health Hum Rights. 2018 Jun;20(1):225-236
pubmed: 30008565
Reprod Health. 2011 Dec 22;8:39
pubmed: 22192901
Reprod Health Matters. 2011 May;19(37):133-43
pubmed: 21555094
Lancet. 2006 Nov 25;368(9550):1887-92
pubmed: 17126721
BMC Pregnancy Childbirth. 2020 Mar 29;20(1):184
pubmed: 32223759
Lancet. 2006 Oct 7;368(9543):1248-53
pubmed: 17027730
Health Policy Plan. 2017 Apr 1;32(3):305-313
pubmed: 27616307
Int J Gynaecol Obstet. 2015 Feb;128(2):160-4
pubmed: 25468057
Lancet. 2001 Aug 11;358(9280):483-8
pubmed: 11513933
Reprod Health. 2017 Oct 27;14(1):139
pubmed: 29078777
Cochrane Database Syst Rev. 2010 Sep 08;(9):CD001993
pubmed: 20824830
Contraception. 2012 Jul;86(1):74-8
pubmed: 22464405
Contraception. 2011 Jun;83(6):504-10
pubmed: 21570546
BMC Health Serv Res. 2014 Jan 21;14:28
pubmed: 24447321
Lancet. 2001 Aug 4;358(9279):397-400
pubmed: 11502338
Int J Gynaecol Obstet. 2010 Nov;111(2):131-5
pubmed: 20801444
Cochrane Database Syst Rev. 2017 Jan 31;1:CD007223
pubmed: 28138973
Lancet. 2006 Nov 25;368(9550):1908-19
pubmed: 17126724
J Gynecol Obstet Biol Reprod (Paris). 2014 Feb;43(2):179-89
pubmed: 24457021
PLoS One. 2017 Apr 3;12(4):e0173639
pubmed: 28369114
Int J Gynaecol Obstet. 2014 Sep;126(3):223-6
pubmed: 24893962
Int J Gynaecol Obstet. 2007 Dec;99 Suppl 2:S168-71
pubmed: 17961571
Cochrane Database Syst Rev. 2015 Nov 10;(11):CD009954
pubmed: 26559875
J Obstet Gynaecol Can. 2006 Nov;28(11):974-979
pubmed: 17169222
BJOG. 2007 Nov;114(11):1363-7
pubmed: 17803714
BMC Health Serv Res. 2015 Dec 17;15:562
pubmed: 26677840
Int J Gynaecol Obstet. 2007 Sep;98(3):222-6
pubmed: 17610879
Reprod Health. 2019 Feb 19;16(1):20
pubmed: 30782201
Int Perspect Sex Reprod Health. 2013 Jun;39(2):88-96
pubmed: 23895885
Milbank Q. 2004;82(4):581-629
pubmed: 15595944